Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Coivas vs TD Tele-Doc Weight Loss

Coivas
Graded #194

Higher grade

vs+4.400000000000006
TD Tele-Doc Weight Loss
Graded #286

Lower grade

The verdict

Coivas takes it — 66.2/100 to 61.8/100.

Coivas grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Coivas is an all-inclusive GLP-1 telehealth service operated by WellVi LLC (d/b/a Coivas) with prescriptions through Arora Health & Aesthetics, LLC.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueCoivas +25
70
45
Dose & formulationCoivas +11
64
53
Clinical oversightTD Tele-Doc Weight Loss +4
84
88
Labs & monitoringTD Tele-Doc Weight Loss +11
54
65
FulfillmentCoivas +10
78
68
Contract termsTD Tele-Doc Weight Loss +35
20
55
Coivas · left barTD Tele-Doc Weight Loss · right bar

The numbers

MetricCoivasTD Tele-Doc Weight Loss
WeighScore66.2/10061.8/100
GradeCC
Scorecard rank#194#286
Semaglutide$149/mo (quarterly plan, compounded)Not disclosed
Tirzepatide$229/mo (quarterly plan, compounded)Not disclosed
CoverageCoverage not published2 states
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyInjection only
Coivas

Graded #194 · C

Strengths

  • All-inclusive pricing: one price covers doctor consult, prescription, shipping and support
  • Compounded semaglutide from $149/mo and tirzepatide from $229/mo on the quarterly plan
  • Names its clinical provider (Arora Health & Aesthetics, LLC) and cites USP 797 / NABP-accredited pharmacies
  • Available in all 50 states; 24/7 support; HSA/FSA eligible; money-back guarantee
  • Most patients approved in under 2 hours; refund if no provider visit or prescription occurs

Where it loses points

  • Dispensing pharmacies described only by category (503A/503B, NABP-accredited) - not named individually
  • Lower quarterly headline price requires a 3-month commitment; monthly plan costs more ($179/$289)
  • Money-back guarantee has strict adherence/verification conditions and no partial/prorated refunds
  • No brand-name Wegovy/Zepbound/Mounjaro/Ozempic - compounded injectable only; binding NY arbitration
TD Tele-Doc Weight Loss

Graded #286 · C

Strengths

  • Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
  • 100% virtual — weekly appointments with board-certified MDs from home; no travel required
  • Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
  • In-network with most commercial insurance plans; may cover visits and monitoring equipment
  • Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)

Where it loses points

  • No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
  • Telehealth available only in Virginia and Maryland; no national reach confirmed
  • No Medicare or Medicaid accepted; limited to commercial insurance plans only
  • No LegitScript certification found; compounded availability and specific pricing undisclosed on site
  • Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard